Company intelligence / Profile preview

Oxymap

Reykjavik, Iceland

Ownership: Private
Development stage: Other

Overview

The Oxymap T1 enables non-invasive measurement of retinal oxygen saturation and vessel width. It provides objective metabolic and structural data for diagnosing and monitoring eye diseases. The product has been adopted by international institutions for clinical research and practice. Early studies suggest potential utility beyond ophthalmology in neurological disease assessment.

Therapeutic areas: OphthalmologyNeurology
Modalities: DeviceSoftware (retinal oximetry imaging system)
Industry: Medical Imaging

Partnerships

University of Iceland (academic collaboration during development)

Beyond the preview

Go deeper on Oxymap.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oxymap.

Explore the full profile